导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.54% | 1592/4773 |
| 近一周 | -3.27% | 3979/5462 |
| 近一月 | -10.19% | 4993/5421 |
| 近一季 | -18.96% | 4781/5209 |
| 近半年 | -0.71% | 1365/4920 |
| 近一年 | 7.63% | 1279/4366 |
| 近两年 | 117.81% | 410/2954 |
| 近三年 | 68.03% | 330/2253 |
| 成立以来 | 27.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.58% 1864/4961 |
36.96% 865/5312 |
- - |
- - |
| 2025 | 52.80% 402/4813 |
-1.48% 2673/3635 |
3.57% 990/4076 |
50.91% 288/4524 |
-0.77% 2633/4813 |
| 2024 | 13.64% 1123/3463 |
-3.98% 1593/2808 |
-6.76% 2007/3014 |
29.14% 173/3129 |
-1.72% 1805/3463 |
| 2023 | -19.30% 1849/2656 |
2.07% 1454/2280 |
-7.26% 1820/2385 |
-9.62% 1859/2515 |
-5.68% 1460/2655 |
| 2022 | -29.41% 1600/2207 |
-20.08% 1519/1919 |
6.03% 783/2016 |
-18.63% 1727/2113 |
2.38% 956/2208 |
| 2021 | 12.02% 392/1822 |
-7.05% 1055/1255 |
26.37% 72/1330 |
-6.80% 991/1466 |
2.32% 626/1822 |
| 2020 | - - |
- - |
- - |
- - |
15.00% 238/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 融通创业板ETF VS. 长安沪深300非周期A(740101) |